LOGOS CAPITAL
Logos Capital is a fundamental biotechnology-focused fund that seeks to combine in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare. Based in San Francisco, Logos combines expertise across medical, scientific, and statistical disciplines to expand the depth of diligence in identifying compelling investment ideas and uncorrelated-market returns. They combine scientific diligence with their statistical modeling of clinical trials to achieve the highest levels of conviction in each position.
LOGOS CAPITAL
Social Links:
Industry:
Biotechnology Hedge Funds
Founded:
2019-01-01
Status:
Active
Contact:
+1 415 747 7342
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Wordpress Plugins Nginx
Similar Organizations
DTC Capital
DTC Capital is a Fundamentals-Focused Crypto Investment Fund.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-06-13 | Elektrofi | Logos Capital investment in Series B - Elektrofi | 40 M USD |
| 2022-04-12 | Grain | Logos Capital investment in Series A - Grain | 16 M USD |
| 2022-04-06 | Triana Biomedicines | Logos Capital investment in Series A - Triana Biomedicines | 110 M USD |
| 2022-02-17 | Synthego | Logos Capital investment in Series E - Synthego | 200 M USD |
| 2022-02-15 | Parse Biosciences | Logos Capital investment in Series B - Parse Biosciences | 41.5 M USD |
| 2022-01-27 | Septerna | Logos Capital investment in Series A - Septerna | 100 M USD |
| 2022-01-27 | Simcha Therapeutics | Logos Capital investment in Series B - Simcha Therapeutics | 40 M USD |
| 2022-01-19 | Enliven Therapeutics | Logos Capital investment in Series B - Enliven Therapeutics | 85 M USD |
| 2021-12-07 | Freenome | Logos Capital investment in Series D - Freenome | 300 M USD |
| 2021-12-07 | Odyssey Therapeutics | Logos Capital investment in Series A - Odyssey Therapeutics | 218 M USD |